U.S. Markets close in 5 hrs 18 mins
  • S&P 500

    4,574.99
    +0.20 (+0.00%)
     
  • Dow 30

    35,677.35
    -79.53 (-0.22%)
     
  • Nasdaq

    15,297.17
    +61.46 (+0.40%)
     
  • Russell 2000

    2,282.22
    -13.85 (-0.60%)
     
  • Gold

    1,791.00
    -2.40 (-0.13%)
     
  • EUR/USD

    1.1618
    +0.0016 (+0.1394%)
     
  • 10-Yr Bond

    1.5750
    -0.0440 (-2.72%)
     
  • Vix

    16.03
    +0.05 (+0.31%)
     
  • GBP/USD

    1.3725
    -0.0038 (-0.2772%)
     
  • USD/JPY

    113.6610
    -0.4680 (-0.4101%)
     
  • BTC-USD

    59,203.54
    -2,847.90 (-4.59%)
     
  • CMC Crypto 200

    1,422.78
    -51.55 (-3.50%)
     
  • FTSE 100

    7,258.05
    -19.57 (-0.27%)
     
  • Nikkei 225

    29,098.24
    -7.76 (-0.03%)
     

Lumos Pharma to Participate in the Jefferies 2020 Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

AUSTIN, Texas, May 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the company will present at the virtual Jefferies 2020 Healthcare Conference on Tuesday, June 2, 2020, at 4:30PM ET. Throughout that same day, Lumos Pharma management will also participate in one-on-one calls with investors. Please contact your Jefferies sales representative to schedule a one-on-one call with our management team.

A live webcast of the presentation will be available on the Company’s website in the “Investors & Media” section under “Events and Presentations.” Listeners may also access the webcast through the following link: http://wsw.com/webcast/jeff126/lumo/. An archived edition of the presentation will be available on the Company’s website later in the day.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-648-3757
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.